藥品參考
Erlotinib
Erlotinib is a medicine in the class oncology. It is used for lung cancer.
- 藥物類別: Oncology
- 用途: lung cancer
最後更新
僅供醫療專業人員參考。本頁為簡要摘要，並非醫療建議，亦不能取代官方仿單或臨床判斷。開立處方或調劑前請務必核實。
本頁的臨床內容僅提供英文版。
重點資訊
- 藥物類別
- Oncology
- ATC 代碼
- L01EB02
- 常見劑型
- 錠劑
- 常見規格
- 150 mg, 100 mg
- 已知交互作用
- 133 (嚴重: 28 · 中度: 77 · 輕微: 28)
- 商品名
- 12
- 國家與市場
- 4
用途
作用方式
EGF receptor tyrosine kinase inhibitor; TKI inhibition possibly blocks angiogenesis and cellular proliferation
成人常用劑量（仿單摘要）
Non-Small Cell Lung Cancer: 150 mg PO qDay 1 hr before or 2 hrs after meals
懷孕與哺乳
- 懷孕
- Unsafe Can cause fetal harm: embryo-fetal death and abortion in rabbits at 3 times human exposure; limited human data. Avoid; women should use effective contraception during and for 1 month after the last dose.
- 哺乳
- Unsafe No milk data; its long half-life may allow build-up in the infant. Because of possible serious reactions (lung, liver, skin), do not breastfeed during treatment and for 2 weeks after the last dose.
已通報的副作用
- Fatigue
- Diarrhea
- Nausea
- Anorexia
- Rash
- Stomatitis
哪些人需要特別留意
- Potentially fatal GI perforations
- Severe bullous, blistering, or exfoliating skin conditions
- Risk of cerebrovascular accident is increased in patients with pancreatic cancer
請告知藥師或醫師您是否懷孕或哺乳、是否患有腎臟或肝臟疾病、是否有過敏，以及您正在使用的所有其他藥物或保健品。
重要交互作用 (133)
- Amobarbital + Erlotinib Major
- Apalutamide + Erlotinib Major
- Carbamazepine + Erlotinib Major
- Cobicistat + Erlotinib Major
- Darunavir + Erlotinib Major
- Dexlansoprazole + Erlotinib Major
- Enzalutamide + Erlotinib Major
- Erlotinib + Esomeprazole Major
- Erlotinib + Etrasimod Major
- Erlotinib + Fosphenytoin Major
同類別的其他藥品
常見問題
What is Erlotinib used for?
Erlotinib is a medicine in the class oncology. It is used for Lung cancer, Pancreatic cancer.
What side effects have been reported with Erlotinib?
Fatigue, Diarrhea, Nausea, Anorexia, Rash, Stomatitis.
Can Erlotinib be taken in pregnancy or while breastfeeding?
Pregnancy: Unsafe. Can cause fetal harm: embryo-fetal death and abortion in rabbits at 3 times human exposure; limited human data. Avoid; women should use effective contraception during and for 1 month after the last dose. Breastfeeding: Unsafe. No milk data; its long half-life may allow build-up in the infant. Because of possible serious reactions (lung, liver, skin), do not breastfeed during treatment and for 2 weeks after the last dose.
What does Erlotinib interact with?
MediHelp lists 133 known interactions for Erlotinib. Major: 28 · Moderate: 77 · Minor: 28. The most serious include Amobarbital, Apalutamide, Carbamazepine.
在 MediHelp App 中取得完整藥品專論、劑量資訊與交互作用檢查
在 MediHelp App 中開啟完整參考資料、檢查多種藥物間的交互作用，並使用劑量工具。
